Why the study?
Do ACE inhibitors and ARBs provide clinical benefits in patients with chronic obstructive pulmonary disease?
Do ACE inhibitors and ARBs provide clinical benefits in patients with chronic obstructive pulmonary disease?
ACE inhibitors and ARBs may offer potential benefits in COPD patients by targeting systemic inflammation and associated cardiovascular comorbidities.
Chronic obstructive pulmonary disease (COPD) is a complex disorder that primarily affects the lungs and is characterized not only by local pulmonary, but also by systemic inflammation which promotes the development of extrapulmonary and cardiovascular co-morbidities. Angiotensin converting enzyme (ACE) inhibitors and ARBs (angiotensin receptor blockers) are widely used drugs in the treatment of cardiovascular diseases, with growing evidence suggesting potential benefits in COPD patients. The purpose of this review is to describe the correlation of renin-angiotensin system (RAS) with COPD pathophysiology and to present the latest data regarding the potential role of RAS blockers in COPD.
No takes yet. Share an insight, caveat, or question.
Vasileiadis et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: